APTOCROM Acquires 50.8B Won Convertible Bond from Affiliate via Loan Set-Off for Financial Restructuring
APTOCROM decided to acquire the 20th series unsecured private convertible bond worth 50.8B KRW issued by its affiliate, Aprogen Biologics
The acquisition price will be settled by offsetting a loan receivable from Aprogen Biologics, resulting in no additional cash outflow
Purpose is to improve financial structure by replacing loans with convertible bonds, potentially enhancing asset soundness
Convertible bond terms: coupon rate 2%, maturity rate 4%, maturity date June 23, 2029, conversion price of 3,778 KRW per common share of Aprogen Biologics
The bond includes a put option allowing early redemption from December 23, 2027 (18 months after issuance) and every 3 months thereafter
Expected acquisition date is June 23, 2026; board resolution passed on May 26, 2026 with one outside director attending
Acquisition amount (50.8B KRW) represents 18.52% of APTOCROM's equity (274.3B KRW), indicating a relatively large asset swap
[AI Summary]This transaction is an asset swap converting a loan receivable into a convertible bond without additional funding, which is a neutral positive for financial restructuring. However, given Aprogen Biologics' deteriorating financials (net loss of 168.3B KRW in 2025), investors should monitor the bond's realizable value and repayment risk.
KOSDAQ Filing Information
Filing: [Correction of Description] Decision on Acquisition of Equity-Linked Bonds